The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant From the National Heart, Lung, and Blood Institute Entitled “Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT”
Doylestown, PA. May 17, 2014– FCCDC is pleased to announce that it has been awarded an Phase I STTR grant (R41HL123126) from the National Heart, Lung, and Blood Institute entitled “Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT” ($225,500). Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy. Heparin is a naturally-occurring anticoagulant that prevents the formation of clots within the vasculature. As a large number of hospitalized patients are exposed to heparin, HIT is a major treatment-induced cause of morbidity and mortality in this patient population. The Principal Investigator is Prof. Bruce Sachais of the University of Pennsylvania.